An ulcer is formed due to the imbalance caused in between aggressive and defensive factors. In case of peptic ulcer, excessive secretion of acid and pepsin, which causes damage in the stomach lining, results in the ulcer formation. A peptic ulcer occurs when an excessive quantity of acidic digestive juices is released by the stomach cells. Ulcer pain usually occurs when the stomach is empty. Often, untreated ulcers can result in further complications in the form of perforation developed in the lining of stomach of small intestine. This causes internal bleeding, which results in blood loss and requires hospitalization. The formation of scar tissues make it difficult for food to pass through the digestive tract. According to the CDC, around 25 million Americans had ulcer during some time in their life. An ulcer can be caused to any person irrespective of age. Usually, women are affected less as compared with men. Furthermore, in the US, around 5,00,000-8,50,000 new cases of ulcer are witnessed every year. Consequently, Technavio’s market research analysts has estimated that with the rising incidences of peptic ulcer, the drug development for peptic ulcer is expected to increase considerably in the upcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for peptic ulcer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development molecules for the treatment of peptic ulcer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
Therapeutic assessment of the drug development for peptic ulcer by route of administration
The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development for peptic ulcer by therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development for peptic ulcer are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
What are the drug development molecules in the various development stages for peptic ulcer?
What are the companies that are currently involved in the drug development for peptic ulcer?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.